# Preclinical optimization of a parasiticidal drug for cryptosporidiosis

> **NIH NIH R01** · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · 2020 · $620,271

## Abstract

PROJECT SUMMARY
Cryptosporidiosis is amongst the most important causes of life-threatening diarrhea in children globally, causes
incurable diarrhea in AIDS and transplant patients, and is the most common cause of waterborne diarrheal
outbreaks in the United States. Almost all human cases of cryptosporidiosis are due to infection of the small
intestinal epithelium with one of two species of Cryptosporidium parasites, C. parvum or C. hominis.
Nitazoxanide, the only approved drug, is efficacious in otherwise healthy adults, but unfortunately, has limited
efficacy (~56%) in children and is equivalent to a placebo in AIDS patients. The long-term goal of this research
program is to develop improved drugs to treat cryptosporidiosis. In this project, a parasiticidal piperazine-
based lead compound with extraordinary in vivo efficacy that was identified by phenotypic screening will be
optimized, and its molecular mechanism of action will be determined. The lead optimization program is guided
by an ideal target product profile and milestones to provide a pre-clinical lead that is likely to be effective in all
patient populations affected by Cryptosporidium and has safety characteristics suitable for treatment of infants,
minimal drug-drug interactions, minimal oral dosing requirements, stability in the tropics, and a low
manufacturing cost. The methods for lead optimization bring together novel in vitro assays and a highly
immunocompromised mouse model of cryptosporidiosis with well-established pharmacology and medicinal
chemistry approaches. For this, cyclic rounds of chemical synthesis will be combined with in vitro
Cryptosporidium assays, in vitro ADME studies, mouse PK studies, and a chronic mouse model of C. parvum
infection. A piglet model will then be used to test clinical efficacy against C. hominis. The method for drug
target identification will take advantage of the lead compound's activity against related malaria parasites to
identify mutations associated with drug resistance and candidate drug targets, followed by CRISPR/Cas9
validation of mutations in C. parvum and biochemical methods to assess direct protein-drug interactions.
Success would yield an optimized clinical candidate that is ready to be advanced to testing in regulatory
toxicology studies, and a validated drug target that will accelerate drug development by enabling target-based
drug design and target-based screening efforts to identify additional chemotypes. Given the dire need for new
cryptosporidiosis drugs, the public health impact of success could be extremely significant.

## Key facts

- **NIH application ID:** 9882947
- **Project number:** 5R01AI143951-02
- **Recipient organization:** UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
- **Principal Investigator:** David Griggs
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $620,271
- **Award type:** 5
- **Project period:** 2019-03-01 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9882947

## Citation

> US National Institutes of Health, RePORTER application 9882947, Preclinical optimization of a parasiticidal drug for cryptosporidiosis (5R01AI143951-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9882947. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*